Head, Quantitative Pharmacology & Pharmacometrics – Oncology

Merck & Co.; Rahway (NJ); Hybrid; USD 282,000 - 444,000; Full time

Benefits offered by this job

Medical insurance

Dental insurance

Vision insurance

401(k) retirement plan

Paid holidays

Vacation days

Sick days

Hybrid work arrangement

Job summary

Merck & Co. in Rahway, NJ, seeks a Head of Quantitative Pharmacology & Pharmacometrics (QP2) Oncology to lead pharmacology strategy for the oncology pipeline and to shape dose, schedule, and patient-selection decisions across development stages.

The role requires a Ph.D. with 15+ years in drug development, including 5+ years in oncology, and deep expertise in pharmacometrics, model-informed drug development, and regulatory strategy. Hybrid work and broad benefits are offered.

Qualifications

• PhD or equivalent in a relevant field with extensive oncology drug development experience.
• Proven impact on model-informed drug development and regulatory strategy.
• Experience leading interdisciplinary teams and regulatory filings for multiple modalities.

Responsibilities

• Lead QP2 Oncology strategy and drive dose/regimen decisions across programs.
• Provide scientific oversight, mentor scientists, and guide governance.
• Shape regulatory interactions and portfolio decisions with cross-functional partners.
• Embed modern quantitative operating model for oncology development.

Skills

Drug development expertise

Model-informed drug development

Regulatory strategy

Team leadership

Population PK/PKPD analyses

AI/ML in pharma

Cross-functional collaboration

Regulatory filings (NDA/MAA)

Education

Ph.D. or equivalent

15+ years in drug development with 5+ in oncology

Background in biopharmaceutics/pharmacometrics/math/statistics

Tools

Pharmacometric software

Job description

Merck & Co. in Rahway, NJ, seeks a Head of Quantitative Pharmacology & Pharmacometrics (QP2) Oncology to lead pharmacology strategy for the oncology pipeline and to shape dose, schedule, and patient-selection decisions across development stages.

The role requires a Ph.D. with 15+ years in drug development, including 5+ years in oncology, and deep expertise in pharmacometrics, model-informed drug development, and regulatory strategy. Hybrid work and broad benefits are offered.